Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
25.45
+0.19 (0.75%)
At close: Dec 5, 2025, 4:00 PM EST
25.97
+0.52 (2.04%)
After-hours: Dec 5, 2025, 7:54 PM EST
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 28.88, with a low estimate of 14 and a high estimate of 56. The average target predicts an increase of 13.48% from the current stock price of 25.45.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 1 | 3 | 3 | 3 |
| Buy | 6 | 5 | 5 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $17 → $26 | Hold | Maintains | $17 → $26 | +2.16% | Nov 28, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | -37.13% | Oct 30, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $54 → $56 | Strong Buy | Maintains | $54 → $56 | +120.04% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | +10.02% | Oct 29, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +13.95% | Oct 20, 2025 |
Financial Forecast
Revenue This Year
242.87M
from 258.00M
Decreased by -5.86%
Revenue Next Year
142.80M
from 242.87M
Decreased by -41.20%
EPS This Year
-3.71
from -3.14
EPS Next Year
-4.24
from -3.71
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 266.7M | 253.0M | ||||
| Avg | 242.9M | 142.8M | ||||
| Low | 224.4M | 36.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.4% | 4.2% | ||||
| Avg | -5.9% | -41.2% | ||||
| Low | -13.0% | -85.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.65 | -3.34 | ||||
| Avg | -3.71 | -4.24 | ||||
| Low | -3.76 | -5.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.